Vima Therapeutics raised $60M in Series A funding, led by Atlas Venture. The funds will expand operations and R&D efforts.

May 30, 2025•7 months ago

Amount Raised

$60 Million

Round Type

series a

CambridgeTherapeuticsBiotechnologyHealth Care

Investors

CanaanAccess IndustriesAtlas Venture

Description

Vima Therapeutics, a Cambridge, MA-based clinical-stage biotechnology company, raised $60M in Series A funding. The round was led by Atlas Venture, with participation from Access Industries and Canaan. The company intends to use the funds to expand operations and its R&D efforts. Vima is advancing a first-in-class oral therapy in clinical trials.

Company Information

Company

Vima Therapeutics

Location

Cambridge, Massachusetts, United States

About

Vima Therapeutics is a clinical-stage biotechnology company providing treatments for dystonia and related movement disorders. The company is advancing an oral therapy designed to help patients improve control of their movement by targeting the root cause of the disease. It is currently working on VIM0423, a potential first-in-class oral therapy, which is in a Phase 1 clinical trial with plans to move into Phase 2 by the end of 2025.

Related People

2 contacts

Funding Insights

Based on industry data

VC-backed spending patterns

VC-backed companies spend 89% more on sales and 100% more on marketing than bootstrapped peers

Tech investment trends